• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法国的迟发性庞贝病:一项全国性研究的分子特征和流行病学。

Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

机构信息

Department of Neurosciences, University of Padova, Azienda Ospedaliera di Padova, Padova, Italy.

Centre de référence des pathologies neuromusculaires Nord-Est-Ile de France, Hôpital La Pitié-Salpêtrière, AP-HP, Paris, France.

出版信息

J Inherit Metab Dis. 2018 Nov;41(6):937-946. doi: 10.1007/s10545-018-0243-7. Epub 2018 Aug 28.

DOI:
10.1007/s10545-018-0243-7
PMID:30155607
Abstract

Pompe disease (PD) is caused by a deficiency of lysosomal acid α-glucosidase resulting from mutations in the GAA gene. The clinical spectrum ranges from a rapidly fatal multisystemic disorder (classic PD, onset < 1 year) to a milder adult onset myopathy. The aims of this study were to characterize the GAA mutations, to establish the disease epidemiology, and to identify potential genotype-phenotype correlations in French late-onset PD patients (onset ≥ 2 years) diagnosed since the 1970s. Data were collected from the two main laboratories involved in PD diagnosis and from the French Pompe registry. Two hundred forty-six patients (130 females and 116 males) were included, with a mean age at diagnosis of 43 years. Eighty-three different mutations were identified in the GAA gene, among which 28 were novel. These variants were spread all over the sequence and included 42 missense (one affecting start codon), 8 nonsense, 15 frameshift, 14 splice mutations, 3 small in-frame deletions, and one large deletion. The common c.-32-13T>G mutation was detected in 151/170 index cases. Other frequent mutations included the exon 18 deletion, the c.525del, and the missense mutations c.1927G>A (p.Gly643Arg) and c.655G>A (p.Gly219Arg). Patients carrying the c.-32-13T>G mutation had an older mean age at onset than patients non-exhibiting this mutation (36 versus 25 years). Patients with the same genotype had a highly variable age at onset. We estimated the frequency of late-onset PD in France around 1/69,927 newborns. In conclusion, we characterized the French cohort of late-onset PD patients through a nationwide study covering more than 40 years.

摘要

庞贝病(PD)是由于 GAA 基因突变导致溶酶体酸性α-葡萄糖苷酶缺乏引起的。临床表现范围从快速致命的多系统疾病(经典 PD,发病年龄<1 岁)到较温和的成人发病肌病。本研究的目的是描述 GAA 突变,建立疾病流行病学,并确定自 20 世纪 70 年代以来诊断的法国迟发性 PD 患者(发病年龄≥2 岁)的潜在基因型-表型相关性。数据来自参与 PD 诊断的两个主要实验室和法国庞贝氏症登记处。共纳入 246 例患者(130 名女性和 116 名男性),诊断时的平均年龄为 43 岁。在 GAA 基因中发现了 83 种不同的突变,其中 28 种是新的。这些变异分布在整个序列中,包括 42 种错义突变(一种影响起始密码子)、8 种无义突变、15 种移码突变、14 种剪接突变、3 种小框内缺失和 1 种大片段缺失。在 151/170 例索引病例中检测到常见的 c.-32-13T>G 突变。其他常见的突变包括外显子 18 缺失、c.525del 和错义突变 c.1927G>A(p.Gly643Arg)和 c.655G>A(p.Gly219Arg)。携带 c.-32-13T>G 突变的患者发病年龄的平均值大于未携带该突变的患者(36 岁与 25 岁)。具有相同基因型的患者发病年龄差异很大。我们估计法国迟发性 PD 的发病率约为每 69927 名新生儿中有 1 例。总之,我们通过一项涵盖 40 多年的全国性研究,对法国迟发性 PD 患者队列进行了特征描述。

相似文献

1
Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.法国的迟发性庞贝病:一项全国性研究的分子特征和流行病学。
J Inherit Metab Dis. 2018 Nov;41(6):937-946. doi: 10.1007/s10545-018-0243-7. Epub 2018 Aug 28.
2
Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.具有相同c.-32-13T->G单倍型的庞贝病患者表现出广泛的症状。
Neurology. 2007 Jan 9;68(2):110-5. doi: 10.1212/01.wnl.0000252798.25690.76.
3
Pompe disease in a Brazilian series: clinical and molecular analyses with identification of nine new mutations.巴西 Pompe 病系列研究:临床与分子分析及 9 种新突变的鉴定
J Neurol. 2009 Nov;256(11):1881-90. doi: 10.1007/s00415-009-5219-y. Epub 2009 Jul 9.
4
Novel GAA mutations in patients with Pompe disease.庞贝病患者中的新型酸性α-葡萄糖苷酶基因突变
Gene. 2015 Apr 25;561(1):124-31. doi: 10.1016/j.gene.2015.02.023. Epub 2015 Feb 12.
5
A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.一项关于庞贝病德国患者的 GAA 基因分子分析、临床表现及基因型-表型相关性的横断面单中心研究。
Orphanet J Rare Dis. 2012 Jun 7;7:35. doi: 10.1186/1750-1172-7-35.
6
Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid α-glucosidase activity.晚期庞贝病患者酸性α-葡萄糖苷酶活性低的分子分析和蛋白加工。
Muscle Nerve. 2011 May;43(5):665-70. doi: 10.1002/mus.21933.
7
The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.法国庞贝氏症登记处。126 例成年庞贝氏症患者队列的基线特征。
Rev Neurol (Paris). 2013 Aug-Sep;169(8-9):595-602. doi: 10.1016/j.neurol.2013.07.002. Epub 2013 Sep 3.
8
Phenotypic implications of pathogenic variant types in Pompe disease.庞贝病致病性变异类型的表型影响。
J Hum Genet. 2021 Nov;66(11):1089-1099. doi: 10.1038/s10038-021-00935-9. Epub 2021 May 11.
9
Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.中国大陆晚发型庞贝病患者的临床及GAA基因突变分析:确定c.2238G>C为最常见突变
BMC Med Genet. 2014 Dec 20;15:141. doi: 10.1186/s12881-014-0141-2.
10
Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.ADVANCE 基线数据集的临床特征和基因型,这是一个全面的美国儿童和青少年庞贝病队列。
Genet Med. 2019 Nov;21(11):2543-2551. doi: 10.1038/s41436-019-0527-9. Epub 2019 May 14.

引用本文的文献

1
Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review.庞贝病诊断方法与流行病学估计的全球差异:一项范围综述的结果
Orphanet J Rare Dis. 2025 May 6;20(1):216. doi: 10.1186/s13023-025-03679-3.
2
Navigating Pompe Disease Assessment: A Comprehensive Scoping Review.庞贝病评估指南:一项全面的范围综述
Cureus. 2024 Nov 13;16(11):e73593. doi: 10.7759/cureus.73593. eCollection 2024 Nov.
3
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).

本文引用的文献

1
Newborn Screening for Pompe Disease.新生儿庞贝氏病筛查。
Pediatrics. 2017 Jul;140(Suppl 1):S4-S13. doi: 10.1542/peds.2016-0280C.
2
Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.通过对常见的 c.-32-13T>G“迟发型”GAA 变异的新生儿筛查,深入了解庞贝病患儿的表型。
Mol Genet Metab. 2017 Nov;122(3):99-107. doi: 10.1016/j.ymgme.2017.09.008. Epub 2017 Sep 19.
3
The emerging phenotype of late-onset Pompe disease: A systematic literature review.
欧洲代谢疾病参考网络(MetabERN)对庞贝病(酸性麦芽糖酶缺乏症,糖原贮积症 II 型)的临床路径建议。
Orphanet J Rare Dis. 2024 Nov 1;19(1):408. doi: 10.1186/s13023-024-03373-w.
4
Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database.法国庞贝病患者院内使用阿糖苷酶α的真实世界数据:来自国家索赔数据库的结果
J Neurol. 2024 Sep;271(9):5846-5852. doi: 10.1007/s00415-024-12543-6. Epub 2024 Jul 4.
5
Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.在接受阿加糖酶α治疗后病情恶化的晚发性庞贝病患者中转换使用阿伐糖苷酶α治疗 1 年后的真实疗效:一项法国队列研究。
Eur J Neurol. 2024 Jul;31(7):e16292. doi: 10.1111/ene.16292. Epub 2024 Apr 8.
6
Pompe disease in China: clinical and molecular characteristics.中国的庞贝病:临床与分子特征
Front Cardiovasc Med. 2023 Dec 14;10:1261172. doi: 10.3389/fcvm.2023.1261172. eCollection 2023.
7
A Comprehensive Update on Late-Onset Pompe Disease.晚期庞贝病的全面更新。
Biomolecules. 2023 Aug 22;13(9):1279. doi: 10.3390/biom13091279.
8
Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.2022 年法国庞贝氏症登记研究:法国迟发性庞贝病患者的特征。
Neurology. 2023 Aug 29;101(9):e966-e977. doi: 10.1212/WNL.0000000000207547. Epub 2023 Jul 7.
9
Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions.家庭输注阿加糖酶α治疗晚发型庞贝病的安全性:18380 次输注经验总结
BioDrugs. 2023 Sep;37(5):685-698. doi: 10.1007/s40259-023-00609-2. Epub 2023 Jun 16.
10
An artificial intelligence-based approach for identifying rare disease patients using retrospective electronic health records applied for Pompe disease.一种基于人工智能的方法,利用回顾性电子健康记录识别庞贝病罕见病患者。
Front Neurol. 2023 Apr 21;14:1108222. doi: 10.3389/fneur.2023.1108222. eCollection 2023.
晚发型庞贝病的新出现表型:一项系统文献综述。
Mol Genet Metab. 2017 Mar;120(3):163-172. doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11.
4
Analysis of protein-coding genetic variation in 60,706 humans.对60706名人类的蛋白质编码基因变异进行分析。
Nature. 2016 Aug 18;536(7616):285-91. doi: 10.1038/nature19057.
5
Should patients with asymptomatic pompe disease be treated? A nationwide study in France.无症状庞贝病患者是否应接受治疗?法国的一项全国性研究。
Muscle Nerve. 2015 Jun;51(6):884-9. doi: 10.1002/mus.24653. Epub 2015 Apr 2.
6
Genotype-phenotype correlation in Pompe disease, a step forward.庞贝病的基因型-表型相关性研究取得进展。
Orphanet J Rare Dis. 2014 Aug 8;9:102. doi: 10.1186/s13023-014-0102-z.
7
Phenotypical variation within 22 families with Pompe disease.22 个庞贝病家系的表型变异。
Orphanet J Rare Dis. 2013 Nov 19;8:182. doi: 10.1186/1750-1172-8-182.
8
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.迟发性糖原贮积症 II 型的扩展表型描述和新的分子发现:意大利北部的人群研究和文献复习。
J Neurol. 2014 Jan;261(1):83-97. doi: 10.1007/s00415-013-7137-2. Epub 2013 Oct 25.
9
Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents.GAA 基因常见 c.-32-13T>G 突变的功能特征:潜在治疗药物的鉴定。
Nucleic Acids Res. 2014 Jan;42(2):1291-302. doi: 10.1093/nar/gkt987. Epub 2013 Oct 22.
10
The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease.法国庞贝氏症登记处。126 例成年庞贝氏症患者队列的基线特征。
Rev Neurol (Paris). 2013 Aug-Sep;169(8-9):595-602. doi: 10.1016/j.neurol.2013.07.002. Epub 2013 Sep 3.